Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Executive Summary
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
You may also be interested in...
Brand Firm In-House Generics Unlikely To Grab Large Market Share – Analyst
Brand companies that launch their own generics are unlikely to capture significant market share but will exert pricing pressure on the ANDA first-filer, a Lehman Brothers analyst said
Brand Firm In-House Generics Unlikely To Grab Large Market Share – Analyst
Brand companies that launch their own generics are unlikely to capture significant market share but will exert pricing pressure on the ANDA first-filer, a Lehman Brothers analyst said
Pfizer Accupril “Branded Generic” Plans Challenged By Teva
Pfizer should be required to obtain a supplemental NDA approval for Accupril before marketing a "branded generic" version of the ACE inhibitor, Teva told FDA in a June 9 1citizen petition